Molecular Templates, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Organization and Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Merger Agreement with Molecular Templates - Additional Information (Detail)

v3.7.0.1

Merger Agreement with Molecular Templates - Additional Information (Detail) - USD ($)	Jun. 23, 2017	Mar. 16, 2017	Jun. 01, 2017	Mar. 24, 2017
Longitude Ventures and Other Investors
Business Acquisition [Line Items]
Commitment to purchase equity securities under equity commitment letter		$ 20,000,000
Amount of additional equity commitments to be secured for equity commitment letter		20,000,000
Expected aggregate amount of concurrent financing		$ 40,000,000
Merger Agreement \| Molecular Templates Inc
Business Acquisition [Line Items]
Molecular Templates equity holders ownership interest		65.60%
Termination fee		$ 800,000
Merger Agreement \| Molecular Templates Inc \| Minimum
Business Acquisition [Line Items]
Amount of qualified financing contingent for repayment of promissory note		10,000,000
Merger Agreement \| Molecular Templates Inc \| Notes
Business Acquisition [Line Items]
Aggregate principal amount		$ 4,000,000
Principal amount			$ 2,000,000	$ 2,000,000
Merger Agreement \| Molecular Templates Inc and Millennium Pharmaceuticals Inc
Business Acquisition [Line Items]
Expected contingent proceeds from stock purchase agreement with Millennium Pharmaceuticals, Inc.	$ 20,000,000
Per share price (pre-reverse split) at which stock will sold to Millennium Pharmaceuticals, Inc.	$ 0.61
Merger Agreement \| Molecular Templates Inc and Millennium Pharmaceuticals Inc \| Minimum
Business Acquisition [Line Items]
Millennium Pharmaceuticals, post closing beneficial ownership percentage limitation	19.00%

- Definition

Amount of additional equity commitments to be secured by Molecular Templates as a contingency to receive amount under equity commitment letter.

+ References

No definition available.

+ Details

Name:	thld_AdditionalEquityCommitmentsContingencyForEquityCommitmentLetter
Namespace Prefix:	thld_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commitment amount to purchase equity securities under equity commitment letter contingent upon close of transaction and securing additional equity commitments.

+ References

No definition available.

+ Details

Name:	thld_CommitmentToPurchaseEquitySecuritiesUnderEquityCommitmentLetter
Namespace Prefix:	thld_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Expected aggregate amount of concurrent financing pursuant to signed equity commitment letters.

+ References

No definition available.

+ Details

Name:	thld_ExpectedAggregateAmountOfConcurrentFinancing
Namespace Prefix:	thld_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Expected proceeds from the stock purchase agreement signed between the Company, Molecular Templates and Millennium Pharmaceuticals, Inc., which is contingent upon the closing of the merger and certain other conditions.

+ References

No definition available.

+ Details

Name:	thld_ExpectedContingentProceedFromStockPurchaseAgreementWithCounterparty
Namespace Prefix:	thld_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Molecular Templates equity holders ownership interest on a fully diluted basis upon consummation of the transaction.

+ References

No definition available.

+ Details

Name:	thld_MIEquityHoldersOwnershipInterest
Namespace Prefix:	thld_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Post closing beneficial ownership percentage limitation of Millennium Pharmaceutical Inc. investment.

+ References

No definition available.

+ Details

Name:	thld_PostCloseBeneficialOwnershipPercentageLimitationOfCounterparty
Namespace Prefix:	thld_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Per share price (pre-reverse split) pursuant to the stock purchase agreement at which equity shares will be sold to Millennium Pharmaceuticals, Inc.

+ References

No definition available.

+ Details

Name:	thld_PreReverseSplitPerPriceForStockToBeSoldToCounterparty
Namespace Prefix:	thld_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Maximum amount that could loaned by Company to Molecular Templates under promissory note agreement.

+ References

No definition available.

+ Details

Name:	thld_PromissoryMaximumNoteAmount
Namespace Prefix:	thld_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of promissory note at the time of close.

+ References

No definition available.

+ Details

Name:	thld_PromissoryNoteAmount
Namespace Prefix:	thld_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Consummation of qualified financing need by Molecular Templates contingent for repayment of promissory note to the Company.

+ References

No definition available.

+ Details

Name:	thld_QualifiedFinancingContingentForRepaymentOfNote
Namespace Prefix:	thld_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Termination fees paid by Company under circumstances upon termination of Merger Agreement.

+ References

No definition available.

+ Details

Name:	thld_TerminationFees
Namespace Prefix:	thld_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=thld_LongitudeVenturesAndOtherInvestorsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=thld_MergerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=thld_MolecularTemplatesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=thld_MolecularTemplatesIncAndMillenniumPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: